Clinical trials: Effectiveness
Dysmenorrhea
Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)
This is a study to determine the overall analgesic effect of a single oral dose of etoricoxib compared to ibuprofen in participants with moderate-to-severe primary dysmenorrhea.
- Trial name
- NCT01462370
- Testing
- Etoricoxib, Ibuprofen, Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
- Volunteers
- 139 people
- Sponsor
- Organon and Co
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Prurigo Nodularis
Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary objective was to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- Trial name
- NCT04501666
- Testing
- Nemolizumab 30 mg
- Where
- 100 sites in United States, Austria and 8 more
- Volunteers
- 286 people
- Sponsor
- Galderma R&D
Myelofibrosis, Primary Myelofibrosis
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551066
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Incyte Corporation
Advanced Prostate Cancer, Lower Urinary Tract Symptoms
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms…
- Trial name
- LEMON (NCT01078545)
- Testing
- Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
- Where
- 143 sites in Poland, Ukraine
- Volunteers
- 729 people
- Sponsor
- Abbott
Psoriasis
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18.
- Trial name
- TIPS (NCT00686686)
- Testing
- Infliximab
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral…
- Trial name
- DUAL™ I China (NCT03172494)
- Testing
- Insulin degludec/liraglutide, Insulin degludec, Liraglutide
- Where
- 36 sites in China
- Volunteers
- 720 people
- Sponsor
- Novo Nordisk A/S
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Non-Small Cell Lung Cancer
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00965731
- Testing
- Erlotinib, PF-02341066
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pfizer
Osteoarthritis
An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis
The purpose of this study is to evaluate the efficacy, safety and effects on Quality of Life (QOL) of tramadol/paracetamol (APAP) as an add-on therapy (medication taken in addition to another medication) in Filipino participants…
- Trial name
- NCT01728246
- Testing
- Tramadol/Paracetamol (APAP), Non-Tramadol/APAP
- Where
- Philippines
- Volunteers
- 473 people
- Sponsor
- Janssen Pharmaceutica
Adolescent Behavior
Effects of Self-efficacy, Planning, and Self-efficacy+Planning Interventions on Body Fat Among Adolescents
This longitudinal experimental study tested the effects of three brief interventions: (1) prompting the formation of plans (or implementation intentions), (2) prompting self-efficacy beliefs, and (3) prompting planning +…
- Trial name
- NCT02689973
- Testing
- Self-Efficacy, Planning, Education
- Where
- Poland
- Volunteers
- 1,217 people, healthy volunteers welcome
- Sponsor
- University of Social Sciences and Humanities, Warsaw
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
- Trial name
- NCT01694966
- Testing
- Methylene Blue MMX®
- Where
- 19 sites in United States, Belgium and 6 more
- Volunteers
- 1,249 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Hypercholesterolemia, Familial
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
The primary objective of this study was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with placebo, on percent change from baseline in LDL-C in adults with heterozygous familial…
- Trial name
- RUTHERFORD (NCT01375751)
- Testing
- Evolocumab
- Volunteers
- 168 people
- Sponsor
- Amgen
Attention Deficit Hyperactivity Disorder (ADHD)
Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting
This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in approximately 100 pediatric patients (aged 6 to 12 years) with ADHD.
- Trial name
- NCT01986062
- Testing
- AR11
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Amyloidosis, Hereditary, Transthyretin Amyloidosis
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis).
- Trial name
- NCT03759379
- Testing
- Patisiran, Vutrisiran
- Where
- 64 sites in United States, Argentina and 20 more
- Volunteers
- 164 people
- Sponsor
- Alnylam Pharmaceuticals
Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Primary Objective: For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with…
- Trial name
- CARMEN-BT01 (NCT04659603)
- Testing
- tusamitamab ravtansine, Gemcitabine
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 50 people
- Sponsor
- Sanofi